Cochrane · systematic review · CD005583

Helicobacter pylori eradication for the prevention of gastric neoplasia

Ford, AC, Yuan, Y, Forman, D, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

Gut2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 1 · 20%Very low 0 · 0%Low 0 · 0%Moderate 4 · 80%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals

Population: healthy asymptomatic H. pylori‐infected individuals

5 questions

Outcome	Effect	Evidence	Status / GRADE
Incidence of gastric cancer ‐ modified ITT analysisHistological examination H. pylori eradication therapy vs control	RR 0.54 [0.4, 0.72]	7 studies · 8323 participants	Moderate Downgraded: risk of bias, inconsistency, publication bias
Death from gastric cancer ‐ modified ITT analysis H. pylori eradication therapy vs control	RR 0.61 [0.4, 0.92]	4 studies · 6301 participants	Moderate Downgraded: risk of bias, inconsistency, publication bias
Death from all causes ‐ modified ITT analysis H. pylori eradication therapy vs control	RR 0.97 [0.85, 1.12]	5 studies · 7079 participants	Moderate Downgraded: risk of bias, inconsistency, publication bias
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis H. pylori eradication therapy vs control	RR 1.22 [0.59, 2.54]	2 studies · 3888 participants	Moderate
Adverse events H. pylori eradication therapy vs control	no estimate extracted	0 studies · 0 participants	Ungraded